Peak rese-cel expansion and transient peripheral B cell depletion occurred by ~2 weeks post infusion​

ir_statement / Aug 8, 2026 / receipt

Peripheral B cells begin repopulating ~2 to 3 months after rese-cel in patients with sufficient follow-up*

ir_statement / Aug 8, 2026 / receipt

Rese-cel expansion & B cell kinetics across indications*

ir_statement / Aug 8, 2026 / receipt

RESET-Myositis†

ir_statement / Aug 8, 2026 / receipt

Highly concentrated treatment network in the US; dermatomyositis represents ~75% of this market

ir_statement / Aug 8, 2026 / receipt

our ability to execute our manufacturing strategy to enable expansion of clinical supply and efficiently scale commercial supply for rese-cel

ir_statement / Aug 8, 2026 / receipt

our ability to grow our autoimmune-focused pipeline

ir_statement / Aug 8, 2026 / receipt

our expectations regarding the potential commercial and economic benefits of preconditioning elimination and automated manufacturing, including its potential to reduce costs of goods, minimize capital

ir_statement / Aug 8, 2026 / receipt

our potential commercial opportunities, including value and addressable market, for our product candidates

ir_statement / Aug 8, 2026 / receipt

↑ total cost of care, human resource and bed space demands

ir_statement / Aug 8, 2026 / receipt

Outpatient administration reduces administrative burden and improves patient and provider accessibility

ir_statement / Aug 8, 2026 / receipt

Reduces use of hospital resources; Increases throughput

ir_statement / Aug 8, 2026 / receipt